{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:05:07Z","timestamp":1782515107270,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,23]]},"DOI":"10.7759\/cureus.74307","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T15:44:06Z","timestamp":1732376646000},"source":"Crossref","is-referenced-by-count":6,"title":["Tapentadol: A Comprehensive Review of Its Role in Pain Management"],"prefix":"10.7759","author":[{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Anch\u00eda-Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Villalobos-Madriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amil","family":"Munich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Quesada-Villase\u00f1or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Hern\u00e1ndez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rodr\u00edguez-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000000366","article-title":"Current issues in postoperative pain management","volume":"33","author":"Rawal N","year":"2016","unstructured":"Rawal N. Current issues in postoperative pain management. Eur J Anaesthesiol. 2016, 33:160-71. 10.1097\/EJA.0000000000000366","journal-title":"Eur J Anaesthesiol"},{"key":"ref2","article-title":"American Chronic Pain Association, Stanford University Division of Pain Medicine: ACPA Stanford Guide To Chronic Pain Management An Integrated Guide to Comprehensive Pain Therapies","year":"2024","unstructured":"ACPA-Stanford resource guide to chronic pain management. an integrated guide to comprehensive pain therapies. American Chronic Pain Association and Stanford University Division of Pain Medicine, Overland Park (KS) and Palo Alto (CA); 2024. https:\/\/www.acpanow.com\/uploads\/9\/9\/8\/3\/99838302\/acpa_stanford_resource_guide_2024.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104901","article-title":"Post-operative pain assessment, management compliance with WHO guidelines and its barriers in hospitals of West Shoa zone, central of Ethiopia, 2021","volume":"84","author":"Temesgen MH","year":"2022","unstructured":"Temesgen MH, Brihanu A, Teshome ZB. Post-operative pain assessment, management compliance with WHO guidelines and its barriers in hospitals of West Shoa zone, central of Ethiopia, 2021. Ann Med Surg (Lond). 2022, 84:104901. 10.1016\/j.amsu.2022.104901","journal-title":"Ann Med Surg (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2018.01.005","article-title":"Tapentadol - a representative of a new class of MOR-NRI analgesics","volume":"70","author":"Zaj\u0105czkowska R","year":"2018","unstructured":"Zaj\u0105czkowska R, Przew\u0142ocka B, Kocot-K\u0119pska M, Mika J, Leppert W, Wordliczek J. Tapentadol - a representative of a new class of MOR-NRI analgesics. Pharmacol Rep. 2018, 70:812-20. 10.1016\/j.pharep.2018.01.005","journal-title":"Pharmacol Rep"},{"key":"ref5","article-title":"Postoperative pain control","author":"Horn R","year":"2024","unstructured":"Horn R, Hendrix JM, Kramer J. Postoperative pain control. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000000681","article-title":"Clinical consequences of inadequate pain relief: barriers to optimal pain management","volume":"134","author":"Baratta JL","year":"2014","unstructured":"Baratta JL, Schwenk ES, Viscusi ER. Clinical consequences of inadequate pain relief: barriers to optimal pain management. Plast Reconstr Surg. 2014, 134:15S-21S. 10.1097\/PRS.0000000000000681","journal-title":"Plast Reconstr Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.46883\/2022.25920973","article-title":"Cancer pain and opioid use disorder","volume":"36","author":"Ganguly A","year":"2022","unstructured":"Ganguly A, Michael M, Goschin S, Harris K, McFarland DC. Cancer pain and opioid use disorder. Oncology (Williston Park). 2022, 36:535-41. 10.46883\/2022.25920973","journal-title":"Oncology (Williston Park)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.162","article-title":"Neuropathic cancer pain: prevalence, pathophysiology, and management","volume":"33","author":"Yoon SY","year":"2018","unstructured":"Yoon SY, Oh J. Neuropathic cancer pain: prevalence, pathophysiology, and management. Korean J Intern Med. 2018, 33:1058-69. 10.3904\/kjim.2018.162","journal-title":"Korean J Intern Med"},{"key":"ref9","article-title":"Efficacy of tapentadol for neuropathic pain in cancer [Article in Japanese]","volume":"48","author":"Takahara Y","year":"2021","unstructured":"Takahara Y, Tanahashi J, Murota K, Imai M, Takagi Y, Kimata T. Efficacy of tapentadol for neuropathic pain in cancer [Article in Japanese]. Gan To Kagaku Ryoho. 2021, 48:811-4.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref10","article-title":"Efficacy of tapentadol ER for managing moderate to severe chronic pain","volume":"16","author":"Afilalo M","year":"2013","unstructured":"Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013, 16:27-40.","journal-title":"Pain Physician"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.12.008","article-title":"Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council","volume":"17","author":"Chou R","year":"2016","unstructured":"Chou R, Gordon DB, de Leon-Casasola OA, et al.. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016, 17:131-57. 10.1016\/j.jpain.2015.12.008","journal-title":"J Pain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01515-z","article-title":"Tapentadol versus tramadol: a narrative and comparative review of their pharmacological, efficacy and safety profiles in adult patients","volume":"81","author":"Roulet L","year":"2021","unstructured":"Roulet L, Rollason V, Desmeules J, Piguet V. Tapentadol versus tramadol: a narrative and comparative review of their pharmacological, efficacy and safety profiles in adult patients. Drugs. 2021, 81:1257-72. 10.1007\/s40265-021-01515-z","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2010.05.005","article-title":"Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain","volume":"14","author":"Schr\u00f6der W","year":"2010","unstructured":"Schr\u00f6der W, Vry JD, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain. 2010, 14:814-21. 10.1016\/j.ejpain.2010.05.005","journal-title":"Eur J Pain"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2010.06.017","article-title":"Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?","volume":"14","author":"Kress HG","year":"2010","unstructured":"Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?. Eur J Pain. 2010, 14:781-3. 10.1016\/j.ejpain.2010.06.017","journal-title":"Eur J Pain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.611494","article-title":"Systematic review of tapentadol in chronic severe pain","volume":"27","author":"Riemsma R","year":"2011","unstructured":"Riemsma R, Forbes C, Harker J, et al.. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin. 2011, 27:1907-30. 10.1185\/03007995.2011.611494","journal-title":"Curr Med Res Opin"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.696097","article-title":"Mechanistic and functional differentiation of tapentadol and tramadol","volume":"13","author":"Raffa RB","year":"2012","unstructured":"Raffa RB, Buschmann H, Christoph T, et al.. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012, 13:1437-49. 10.1517\/14656566.2012.696097","journal-title":"Expert Opin Pharmacother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2016.29.3.153","article-title":"Tapentadol: can it kill two birds with one stone without breaking windows?","volume":"29","author":"Chang EJ","year":"2016","unstructured":"Chang EJ, Choi EJ, Kim KH. Tapentadol: can it kill two birds with one stone without breaking windows?. Korean J Pain. 2016, 29:153-7. 10.3344\/kjp.2016.29.3.153","journal-title":"Korean J Pain"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.648616","article-title":"Tapentadol for pain: a treatment evaluation","volume":"13","author":"Hartrick CT","year":"2012","unstructured":"Hartrick CT, Rodr\u00edguez Hernandez JR. Tapentadol for pain: a treatment evaluation. Expert Opin Pharmacother. 2012, 13:283-6. 10.1517\/14656566.2012.648616","journal-title":"Expert Opin Pharmacother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bfopcu.2013.04.003","article-title":"Tapentadol, a novel analgesic: review of recent trends in synthesis, related substances, analytical methods, pharmacodynamics and pharmacokinetics","volume":"51","author":"Jain D","year":"2013","unstructured":"Jain D, Basniwal PK. Tapentadol, a novel analgesic: review of recent trends in synthesis, related substances, analytical methods, pharmacodynamics and pharmacokinetics. Bull Fac Pharm Cairo Univ (Online). 2013, 51:283-9. 10.1016\/j.bfopcu.2013.04.003","journal-title":"Bull Fac Pharm Cairo Univ (Online)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1072169","article-title":"Unique pharmacology of tapentadol for treating acute and chronic pain","volume":"11","author":"Knezevic NN","year":"2015","unstructured":"Knezevic NN, Tverdohleb T, Knezevic I, Candido KD. Unique pharmacology of tapentadol for treating acute and chronic pain. Expert Opin Drug Metab Toxicol. 2015, 11:1475-92. 10.1517\/17425255.2015.1072169","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/anae.13080","article-title":"Tapentadol--the evidence so far","volume":"70","author":"Ramaswamy S","year":"2015","unstructured":"Ramaswamy S, Chang S, Mehta V. Tapentadol--the evidence so far. Anaesthesia. 2015, 70:518-22. 10.1111\/anae.13080","journal-title":"Anaesthesia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011460.pub2","article-title":"Oral tapentadol for cancer pain","volume":"2015","author":"Wiffen PJ","year":"2015","unstructured":"Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database Syst Rev. 2015, 2015:CD011460. 10.1002\/14651858.CD011460.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009923.pub2","article-title":"Tapentadol for chronic musculoskeletal pain in adults","volume":"2015","author":"Santos J","year":"2015","unstructured":"Santos J, Alarc\u00e3o J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015, 2015:CD009923. 10.1002\/14651858.CD009923.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2016.1229788","article-title":"Comparative metabolism of tramadol and tapentadol: a toxicological perspective","volume":"48","author":"Barbosa J","year":"2016","unstructured":"Barbosa J, Faria J, Queir\u00f3s O, Moreira R, Carvalho F, Dinis-Oliveira RJ. Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metab Rev. 2016, 48:577-92. 10.1080\/03602532.2016.1229788","journal-title":"Drug Metab Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12308","article-title":"Effectiveness of tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 study","volume":"16","author":"Baron R","year":"2016","unstructured":"Baron R, Likar R, Martin-Mola E, et al.. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 study. Pain Pract. 2016, 16:580-99. 10.1111\/papr.12308","journal-title":"Pain Pract"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw154","article-title":"Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and meta-analysis","volume":"18","author":"Xiao JP","year":"2017","unstructured":"Xiao JP, Li AL, Feng BM, Ye Y, Wang GJ. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and meta-analysis. Pain Med. 2017, 18:14-24. 10.1093\/pm\/pnw154","journal-title":"Pain Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1379981","article-title":"The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review","volume":"33","author":"Mercadante S","year":"2017","unstructured":"Mercadante S. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review. Curr Med Res Opin. 2017, 33:1965-9. 10.1080\/03007995.2017.1379981","journal-title":"Curr Med Res Opin"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1196","article-title":"Comparative pharmacology and toxicology of tramadol and tapentadol","volume":"22","author":"Faria J","year":"2018","unstructured":"Faria J, Barbosa J, Moreira R, Queir\u00f3s O, Carvalho F, Dinis-Oliveira RJ. Comparative pharmacology and toxicology of tramadol and tapentadol. Eur J Pain. 2018, 22:827-44. 10.1002\/ejp.1196","journal-title":"Eur J Pain"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-018-0095-8","article-title":"Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain","volume":"7","author":"Pergolizzi JV Jr","year":"2018","unstructured":"Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB, Bisney J. Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain. Pain Ther. 2018, 7:37-57. 10.1007\/s40122-018-0095-8","journal-title":"Pain Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S190154","article-title":"Tapentadol: an overview of the safety profile","volume":"12","author":"Polati E","year":"2019","unstructured":"Polati E, Canonico PL, Schweiger V, Collino M. Tapentadol: an overview of the safety profile. J Pain Res. 2019, 12:1569-76. 10.2147\/JPR.S190154","journal-title":"J Pain Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00932-7","article-title":"Outcomes associated with treatment of chronic pain with tapentadol compared with morphine and oxycodone: a UK primary care observational study","volume":"36","author":"Morgan CL","year":"2019","unstructured":"Morgan CL, Jenkins-Jones S, Currie C, Baxter G. Outcomes associated with treatment of chronic pain with tapentadol compared with morphine and oxycodone: a UK primary care observational study. Adv Ther. 2019, 36:1412-25. 10.1007\/s12325-019-00932-7","journal-title":"Adv Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2023.0018","article-title":"Differences in the analgesic effect of opioids on pain in cancer patients with spinal metastases","volume":"4","author":"Takemura M","year":"2023","unstructured":"Takemura M, Niki K, Okamoto Y, et al.. Differences in the analgesic effect of opioids on pain in cancer patients with spinal metastases. Palliat Med Rep. 2023, 4:220-30. 10.1089\/pmr.2023.0018","journal-title":"Palliat Med Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b21-00212","article-title":"Tapentadol in cancer patients with neuropathic pain: a comparison of methadone, oxycodone, fentanyl, and hydromorphone","volume":"44","author":"Takemura M","year":"2021","unstructured":"Takemura M, Niki K, Okamoto Y, Matsuda Y, Omae T, Takagi T, Ueda M. Tapentadol in cancer patients with neuropathic pain: a comparison of methadone, oxycodone, fentanyl, and hydromorphone. Biol Pharm Bull. 2021, 44:1286-93. 10.1248\/bpb.b21-00212","journal-title":"Biol Pharm Bull"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2021.07.021","article-title":"The effects of tapentadol and oxycodone on central processing of tonic pain","volume":"132","author":"Nedergaard RB","year":"2021","unstructured":"Nedergaard RB, Hansen TM, Nissen TD, Mark EB, Brock C, Drewes AM. The effects of tapentadol and oxycodone on central processing of tonic pain. Clin Neurophysiol. 2021, 132:2342-50. 10.1016\/j.clinph.2021.07.021","journal-title":"Clin Neurophysiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1515\/sjpain-2020-0151","article-title":"Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a\u00a0mechanistic study in healthy volunteers","volume":"21","author":"Mark EB","year":"2021","unstructured":"Mark EB, Fr\u00f8kj\u00e6r JB, Hansen TM, Nedergaard RB, Drewes AM. Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a\u00a0mechanistic study in healthy volunteers. Scand J Pain. 2021, 21:406-14. 10.1515\/sjpain-2020-0151","journal-title":"Scand J Pain"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-12-9","article-title":"Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality","volume":"10","author":"Vellucci R","year":"2021","unstructured":"Vellucci R, De Rosa G, Piraccini E. Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality. Drugs Context. 2021, 10:2020-12-9. 10.7573\/dic.2020-12-9","journal-title":"Drugs Context"},{"key":"ref37","article-title":"Long-term effectiveness and tolerability of pain treatment with tapentadol prolonged release","volume":"24","author":"Mateos RG","year":"2021","unstructured":"Mateos RG, Bernal DS, Morera LM, Ferri CM, Escobar AE. Long-term effectiveness and tolerability of pain treatment with tapentadol prolonged release. Pain Physician. 2021, 24:E75-85.","journal-title":"Pain Physician"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13085-5","article-title":"Oxycodone\/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study","volume":"12","author":"Barrachina J","year":"2022","unstructured":"Barrachina J, Margarit C, Muriel J, et al.. Oxycodone\/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study. Sci Rep. 2022, 12:10126. 10.1038\/s41598-022-13085-5","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06992-w","article-title":"A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-na\u00efve or opioid-resistant patients","volume":"30","author":"Jung JY","year":"2022","unstructured":"Jung JY, Chon HJ, Choi YJ, Yeon SE, Choi SY, Lee KH. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-na\u00efve or opioid-resistant patients. Support Care Cancer. 2022, 30:6103-12. 10.1007\/s00520-022-06992-w","journal-title":"Support Care Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102468","article-title":"Sex differences in oxycodone\/naloxone vs. tapentadol in chronic non-cancer pain: an observational real-world study","volume":"10","author":"Barrachina J","year":"2022","unstructured":"Barrachina J, Margarit C, Muriel J, et al.. Sex differences in oxycodone\/naloxone vs. tapentadol in chronic non-cancer pain: an observational real-world study. Biomedicines. 2022, 10:2468. 10.3390\/biomedicines10102468","journal-title":"Biomedicines"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000641","article-title":"Tapentadol for the management of cancer pain in adults: an update","volume":"17","author":"Boland JW","year":"2023","unstructured":"Boland JW. Tapentadol for the management of cancer pain in adults: an update. Curr Opin Support Palliat Care. 2023, 17:90-7. 10.1097\/SPC.0000000000000641","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S402362","article-title":"Tapentadol: a review of experimental pharmacology studies, clinical trials, and recent findings","volume":"17","author":"Alshehri FS","year":"2023","unstructured":"Alshehri FS. Tapentadol: a review of experimental pharmacology studies, clinical trials, and recent findings. Drug Des Devel Ther. 2023, 17:851-61. 10.2147\/DDDT.S402362","journal-title":"Drug Des Devel Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S190160","article-title":"Pharmacological rationale for tapentadol therapy: a review of new evidence","volume":"12","author":"Romualdi P","year":"2019","unstructured":"Romualdi P, Grilli M, Canonico PL, Collino M, Dickenson AH. Pharmacological rationale for tapentadol therapy: a review of new evidence. J Pain Res. 2019, 12:1513-20. 10.2147\/JPR.S190160","journal-title":"J Pain Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000001425","article-title":"Tapentadol versus oxycodone analgesia and side effects after laparoscopic hysterectomy: a randomised controlled trial","volume":"38","author":"Comelon M","year":"2021","unstructured":"Comelon M, Raeder J, Dr\u00e6gni T, Lieng M, Lenz H. Tapentadol versus oxycodone analgesia and side effects after laparoscopic hysterectomy: a randomised controlled trial. Eur J Anaesthesiol. 2021, 38:995-1002. 10.1097\/EJA.0000000000001425","journal-title":"Eur J Anaesthesiol"},{"key":"ref45","article-title":"Opioid pharmacokinetic drug-drug interactions","volume":"17","author":"Overholser BR","year":"2011","unstructured":"Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011, 17:S276-87.","journal-title":"Am J Manag Care"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1082992","article-title":"Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan","volume":"31","author":"Chen YJ","year":"2015","unstructured":"Chen YJ, Chiang CC, Huang PJ, Huang J, Karcher K, Li H. Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan. Curr Med Res Opin. 2015, 31:2001-9. 10.1185\/03007995.2015.1082992","journal-title":"Curr Med Res Opin"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2015.0270","article-title":"Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency","volume":"11","author":"Eichenbaum G","year":"2015","unstructured":"Eichenbaum G, G\u00f6hler K, Etropolski M, Steigerwald I, Pergolizzi J, Kim M, Vorsanger G. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. J Opioid Manag. 2015, 11:211-27. 10.5055\/jom.2015.0270","journal-title":"J Opioid Manag"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S190171","article-title":"Tapentadol: a new option for the treatment of cancer and noncancer pains","volume":"12","author":"Dickenson AH","year":"2019","unstructured":"Dickenson AH, Kress HG. Tapentadol: a new option for the treatment of cancer and noncancer pains. J Pain Res. 2019, 12:1509-11. 10.2147\/JPR.S190171","journal-title":"J Pain Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S191543","article-title":"Tapentadol in the management of cancer pain: current evidence and future perspectives","volume":"12","author":"Kress HG","year":"2019","unstructured":"Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. J Pain Res. 2019, 12:1553-60. 10.2147\/JPR.S191543","journal-title":"J Pain Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-020-02821-8","article-title":"Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-na\u00efve and opioid-tolerant patients: a retrospective study","volume":"34","author":"Sazuka S","year":"2020","unstructured":"Sazuka S, Koitabashi T. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-na\u00efve and opioid-tolerant patients: a retrospective study. J Anesth. 2020, 34:834-40. 10.1007\/s00540-020-02821-8","journal-title":"J Anesth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/286895-tapentadol-a-comprehensive-review-of-its-role-in-pain-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T15:44:09Z","timestamp":1732376649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/286895-tapentadol-a-comprehensive-review-of-its-role-in-pain-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.74307","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,23]]}}}